Chat with us, powered by LiveChat

Loading...

Antiviral Therapies Market Report

RA00078

Antiviral Therapies Market, By Drug Type (Herpes Antiviral Drugs, Hepatitis Antiviral Drugs, HIV Antiviral Drugs, Influenza Antiviral Drugs, Others), By Distribution Channel (Hospital Pharmacy, Independent Pharmacy & Drug Store, Online Pharmacy): Global Opportunity Analysis and Industry Forecast, 2019–2026

RA00078

Pages: 270

Feb 2020

COVID-19

pandemic has shown to have an enormous impact on most
industries.

Click Here to access our comprehensive analysis of the

Impact of covid-19 on Antiviral Therapies Market

Global Antiviral Therapies Market Overview 2026:

Global Antiviral therapies market size will reach $75.6 billion by 2026, rising from $ 48.1 billion in 2018, at a CAGR of 5.8%. Asia-Pacific antiviral drugs market is expected to grow rapidly throughout the estimated period, and is predicted to reach $75.6 billion by the end of 2026, at a healthy growth rate of 5.8%. This is mainly owing to the increase in the number of HIV infection registered cases, rise in awareness about HIV infection, and growing collaborations between public and private sectors. The North America antiviral drugs market held a leading position in the global antiviral drugs market in 2018. This region is anticipated to hold its lead position in the market by generating a revenue of $29.5 billion by 2026. 

Antiviral drugs are prescription-based drugs that are used for preventing as well as treating viral infections including HIV, hepatitis, herpes, and influenza. These drugs are usually administered in the form of vaccines. They help in reducing the period of flu symptoms and other diseases in adults and neonates and can decrease the rigorousness of these disease symptoms. 

Rising Occurrences of Viral Infections is Anticipated to Drive the Antiviral Therapies Market

Antiviral drugs market is projected to grow at an increasing speed during the projected period due to key factors such as growing occurrences of viral infections, rising public awareness regarding these infections, growth in healthcare spending, increasing investments on R&D, and occurrence of severe and deadly diseases. However, expenses involved in the production of these drugs and growth in the demand for alternative medicines such as homeopathy and naturopathy are predicted to hinder the market growth. Furthermore, development of broad-spectrum antibiotics and increase in rewarding opportunities in the evolving economies of Asia-Pacific and LAMEA regions are likely to offer several opportunities for the development of the market throughout the estimated period. 

Antiviral Drugs Market, By Drug Type: 

HIV Antiviral drugs segment is predicted to be most lucrative in 2018

Antiviral Drugs Market, By Drug Type

The HIV segment in the Antiviral drugs market was accounted for $16.4 billion in the year 2018 and is expected to upsurge at a growth rate of $ 5.4% during the forecast period. This is mainly due to growing occurrence of HIV infections all over the world. The major share of HIV antiviral drug consumption has been observed in the North America. Moreover, the usage of antiviral drugs in African economies is predicted to upsurge the market growth. 

Antiviral Drugs Market, By Distribution Channel:

Online Pharmacy segment is will generate a revenue of $23.2 billion by the year of 2026

Antiviral Drugs Market, By Distribution Channel

 
The online pharmacy segment is estimated to grow at an increased speed by generating a revenue of $23.2 billion by the end of 2026, at a significant growth rate of 6.1% during the estimated period. This is mainly because of the growing trends in the online shopping sector in the developed as well as developing nations. Furthermore, the hospital pharmacy segment held the largest antiviral therapy market share in 2018 accounting for 48% of the overall market globally. 

North America Held the Largest Share of the Market:

North America held a dominant position in the antiviral drug market in 2018 due to factors such as the increasing occurrence of hepatitis C infections and HIV, existence of key players, growing elderly population, rising healthcare awareness, and increasing expenditure over healthcare in this region. However, key factors for instance patent expiration and generic erosion are limiting the market growth in this region. On the contrary, the Asia-Pacific region is projected to observe tremendous growth during the estimated period due to key factors such as increased incidences of HIV infection, rising awareness about HIV infection, along growing collaboration between private and public sectors. 

To explore more about Antiviral Therapies Market, get in touch with our analysts here. https://www.researchdive.com/connect-to-analyst/78

Major Market Players 

The key players listed in the report are Gilead Sciences, F. Hoffmann-La Roche Ltd., AbbVie Inc., GlaxoSmithKline, Abbott Laboratories, Bristol-Myers-Squibb, AstraZeneca Plc., Johnson & Johnson, Schering-Plough Corporation, and Merck & Co., Inc. These market players are mainly involved in activities such as developments in current technology, new product launches, mergers and acquisitions, and geographical expansion to obtain a strong position in the antiviral therapies market. These are some of the growth strategies implemented by these market players. 
 

Aspect

Particulars

  Historical Market Estimations

  2018-2019

  Base Year for Market Estimation

  2018

  Forecast timeline for Market Projection

  2019-2026

  Geographical Scope

  North America, Europe, Asia-Pacific, LAMEA

  Segmentation by Drug Type

  • Herpes Antiviral Drugs
  • Hepatitis Antiviral Drugs
  • HIV Antiviral Drugs
  • Influenza Antiviral Drugs

  Segmentation by Distribution Channel

  • Hospital Pharmacy
  • Independent Pharmacy and Drug Store
  • Online Pharmacy

  Key Countries Covered

U.S., Canada, Germany, France, Spain, Russia, Japan, China, India, South Korea, Australia, Brazil, and Saudi Arabia

  Key Companies Profiled

  • Dr. Reddy’s Laboratories Ltd.
  • Aurobindo Pharma
  • Johnson & Johnson Services, Inc.
  • Merck & Co.
  • GlaxoSmithKline plc.
  • Gilead Sciences Inc.
  • F. Hoffman-La Roche Ltd,
  • Cipla, Inc.
  • Bristol-Myers Squibb Company
  • AbbVie, Inc.

Frequently Asked Questions
 

A. The global Antiviral therapies Market size was over $48.1 billion in 2018, and is further anticipated to reach $75.6 billion by 2026.

A. Dr. Reddy’s Laboratories Ltd., Aurobindo Pharma, and Johnson & Johnson Services, Inc. are some of the key players in the global Antiviral therapies market.

A. Asia Pacific possesses great investment opportunities for the investors to witness the most promising growth in the coming years.

A. Asia Pacific Antiviral therapies Market is projected to grow at 76.5% CAGR during the forecast period.

A. Product development and joint ventures are the key strategies opted by the operating companies in this market.

A. Johnson & Johnson Services Ltd and Dr. Reddy’s Laboratories, ltd. investing more in R&D activities for developing new products and technologies.

1. Research Methodology

1.1. Desk Research
1.2. Real time insights and validation
1.3. Forecast model
1.4. Assumptions and forecast parameters

1.4.1. Assumptions
1.4.2. Forecast parameters

1.5. Data sources

1.5.1. Primary
1.5.2. Secondary

2. Executive Summary

2.1. 360° summary
2.2. Drug Type trends
2.3. Distribution Channel trends

3. Market Overview

3.1. Market segmentation & definitions
3.2. key takeaways

3.2.1. Top investment pockets
3.2.2. Top winning strategies

3.3. Porter’s five forces analysis

3.3.1. Bargaining power of consumers
3.3.2. Bargaining power of suppliers
3.3.3. Threat of new entrants
3.3.4. Threat of substitutes
3.3.5. Competitive rivalry in the market

3.4. Market dynamics

3.4.1. Drivers
3.4.2. Restraints
3.4.3. Opportunities

3.5. Distribution Channel landscape
3.6. Regulatory landscape
3.7. Patent landscape
3.8. Market value chain analysis
3.9. Strategic overview

4. Anti-Viral Therapies Market, by Drug Type

4.1. Herpes Antiviral Drugs

4.1.1. Market size and forecast, by region, 2016-2026
4.1.2. Comparative market share analysis, 2018 & 2026

4.2. Hepatitis Antiviral Drugs

4.2.1. Market size and forecast, by region, 2016-2026
4.2.2. Comparative market share analysis, 2018 & 2026

4.3. HIV Antiviral Drugs

4.3.1. Market size and forecast, by region, 2016-2026
4.3.2. Comparative market share analysis, 2018 & 2026

4.4. Influenza Antiviral Drugs

4.4.1. Market size and forecast, by region, 2016-2026
4.4.2. Comparative market share analysis, 2018 & 2026

4.5. Others

4.5.1. Market size and forecast, by region, 2016-2026
4.5.2. Comparative market share analysis, 2018 & 2026

5. Anti-Viral Therapies Market, by Distribution Channel

5.1. Hospitality Pharmacy

5.1.1. Market size and forecast, by region, 2016-2026
5.1.2. Comparative market share analysis, 2018 & 2026

5.2. Independent Pharmacy and Drug Store

5.2.1. Market size and forecast, by region, 2016-2026
5.2.2. Comparative market share analysis, 2018 & 2026

5.3. Online Pharmacy

5.3.1. Market size and forecast, by region, 2016-2026
5.3.2. Comparative market share analysis, 2018 & 2026

6. Anti-Viral Therapies Market, by Region

6.1. North America

6.1.1. Market size and forecast, by Drug, 2016-2026
6.1.2. Market size and forecast, by Distribution Channel, 2016-2026
6.1.3. Market size and forecast, by country, 2016-2026
6.1.4. Comparative market share analysis, 2018 & 2026
6.1.5. U.S.

6.1.5.1. Market size and forecast, by Drug, 2016-2026
6.1.5.2. Market size and forecast, by Distribution Channel, 2016-2026
6.1.5.3. Comparative market share analysis, 2018 & 2026

6.1.6. Canada

6.1.6.1. Market size and forecast, by Drug, 2016-2026
6.1.6.2. Market size and forecast, by Distribution Channel, 2016-2026
6.1.6.3. Comparative market share analysis, 2018 & 2026

6.1.7. Mexico

6.1.7.1. Market size and forecast, by Drug, 2016-2026
6.1.7.2. Market size and forecast, by Distribution Channel, 2016-2026
6.1.7.3. Comparative market share analysis, 2018 & 2026

6.2. Europe

6.2.1. Market size and forecast, by Drug, 2016-2026
6.2.2. Market size and forecast, by Distribution Channel, 2016-2026
6.2.3. Market size and forecast, by country, 2016-2026
6.2.4. Comparative market share analysis, 2018 & 2026
6.2.5. UK

6.2.5.1. Market size and forecast, by Drug, 2016-2026
6.2.5.2. Market size and forecast, by Distribution Channel, 2016-2026
6.2.5.3. Comparative market share analysis, 2018 & 2026

6.2.6. Germany

6.2.6.1. Market size and forecast, by Drug, 2016-2026
6.2.6.2. Market size and forecast, by Distribution Channel, 2016-2026
6.2.6.3. Comparative market share analysis, 2018 & 2026

6.2.7. France

6.2.7.1. Market size and forecast, by Drug, 2016-2026
6.2.7.2. Market size and forecast, by Distribution Channel, 2016-2026
6.2.7.3. Comparative market share analysis, 2018 & 2026

6.2.8. Spain

6.2.8.1. Market size and forecast, by Drug, 2016-2026
6.2.8.2. Market size and forecast, by Distribution Channel, 2016-2026
6.2.8.3. Comparative market share analysis, 2018 & 2026

6.2.9. Italy

6.2.9.1. Market size and forecast, by Drug, 2016-2026
6.2.9.2. Market size and forecast, by Distribution Channel, 2016-2026
6.2.9.3. Comparative market share analysis, 2018 & 2026

6.2.10. Rest of Europe

6.2.10.1. Market size and forecast, by Drug, 2016-2026
6.2.10.2. Market size and forecast, by Distribution Channel, 2016-2026
6.2.10.3. Comparative market share analysis, 2018 & 2026 

6.3. Asia-Pacific

6.3.1. Market size and forecast, by Drug, 2016-2026
6.3.2. Market size and forecast, by Distribution Channel, 2016-2026
6.3.3. Market size and forecast, by country, 2016-2026
6.3.4. Comparative market share analysis, 2018 & 2026
6.3.5. China

6.3.5.1. Market size and forecast, by Drug, 2016-2026
6.3.5.2. Market size and forecast, by Distribution Channel, 2016-2026
6.3.5.3. Comparative market share analysis, 2018 & 2026

6.3.6. Japan

6.3.6.1. Market size and forecast, by Drug, 2016-2026
6.3.6.2. Market size and forecast, by Distribution Channel, 2016-2026
6.3.6.3. Comparative market share analysis, 2018 & 2026

6.3.7. India

6.3.7.1. Market size and forecast, by Drug, 2016-2026
6.3.7.2. Market size and forecast, by Distribution Channel, 2016-2026
6.3.7.3. Comparative market share analysis, 2018 & 2026

6.3.8. Australia

6.3.8.1. Market size and forecast, by Drug, 2016-2026
6.3.8.2. Market size and forecast, by Distribution Channel, 2016-2026
6.3.8.3. Comparative market share analysis, 2018 & 2026

6.3.9. South Korea

6.3.9.1. Market size and forecast, by Drug, 2016-2026
6.3.9.2. Market size and forecast, by Distribution Channel, 2016-2026
6.3.9.3. Comparative market share analysis, 2018 & 2026

6.3.10. Rest of Asia-Pacific

6.3.10.1. Market size and forecast, by Drug, 2016-2026
6.3.10.2. Market size and forecast, by Distribution Channel, 2016-2026
6.3.10.3. Comparative market share analysis, 2018 & 2026

6.4. LAMEA

6.4.1. Market size and forecast, by Drug, 2016-2026
6.4.2. Market size and forecast, by Distribution Channel, 2016-2026
6.4.3. Market size and forecast, by country, 2016-2026
6.4.4. Comparative market share analysis, 2018 & 2026
6.4.5. Brazil
6.4.6. Market size and forecast, by Drug, 2016-2026
6.4.7. Market size and forecast, by Distribution Channel, 2016-2026
6.4.8. Comparative market share analysis, 2018 & 2026
6.4.9. Saudi Arabia

6.4.9.1. Market size and forecast, by Drug, 2016-2026
6.4.9.2. Market size and forecast, by Distribution Channel, 2016-2026
6.4.9.3. Comparative market share analysis, 2018 & 2026

6.4.10. South Africa

6.4.10.1. Market size and forecast, by Drug, 2016-2026
6.4.10.2. Market size and forecast, by Distribution Channel, 2016-2026
6.4.10.3. Comparative market share analysis, 2018 & 2026

6.4.11. Rest of LAMEA

6.4.11.1. Market size and forecast, by Drug, 2016-2026
6.4.11.2. Market size and forecast, by Distribution Channel, 2016-2026
6.4.11.3. Comparative market share analysis, 2018 & 2026

7. Company Profiles

7.1. AbbVie, Inc.

7.1.1. Business overview
7.1.2. Financial performance
7.1.3. Drug portfolio
7.1.4. Recent strategic moves & developments
7.1.5. SWOT analysis

7.2. Bristol-Myers Squibb Company

7.2.1. Business overview
7.2.2. Financial performance
7.2.3. Drug portfolio
7.2.4. Recent strategic moves & developments
7.2.5. SWOT analysis

7.3. Cipla, Inc. 

7.3.1. Business overview
7.3.2. Financial performance
7.3.3. Drug portfolio
7.3.4. Recent strategic moves & developments
7.3.5. SWOT analysis

7.4. F. Hoffman-La Roche Ltd.

7.4.1. Business overview
7.4.2. Financial performance
7.4.3. Drug portfolio
7.4.4. Recent strategic moves & developments
7.4.5. SWOT analysis

7.5. Gilead Sciences Inc.

7.5.1. Business overview
7.5.2. Financial performance
7.5.3. Drug portfolio
7.5.4. Recent strategic moves & developments
7.5.5. SWOT analysis

7.6. GlaxoSmithKline plc.

7.6.1. Business overview
7.6.2. Financial performance
7.6.3. Drug portfolio
7.6.4. Recent strategic moves & developments
7.6.5. SWOT analysis

7.7. Merck & Co.

7.7.1. Business overview
7.7.2. Financial performance
7.7.3. Drug portfolio
7.7.4. Recent strategic moves & developments
7.7.5. SWOT analysis

7.8. Johnson & Johnson Services, Inc.

7.8.1. Business overview
7.8.2. Financial performance
7.8.3. Drug portfolio
7.8.4. Recent strategic moves & developments
7.8.5. SWOT analysis

7.9. Aurobindo Pharma

7.9.1. Business overview
7.9.2. Financial performance
7.9.3. Drug portfolio
7.9.4. Recent strategic moves & developments
7.9.5. SWOT analysis

7.10. Dr. Reddy’s Laboratories Ltd.

7.10.1. Business overview
7.10.2. Financial performance
7.10.3. Drug portfolio
7.10.4. Recent strategic moves & developments
7.10.5. SWOT analysis

In the past few years, there has been a considerable demand for antiviral therapies from the developing as well as developed countries. A large number of people all around the world are relying on antiviral drugs to treat several diseases. A few years ago, the similar population base was relied on home remedies to cure infections and uncomplicated diseases. This kept these anti-viral therapies market to develop at a sluggish rate. However, in the recent years, advancements in medical sciences and technology have created a huge availability of these drugs. Earlier, antiviral drugs were referred as some sort of luxury, but with the help of these developments, the antiviral drugs became easily available to common masses and the production rate also doubled. Certainly, the reliance over home remedies and cure decreased as there came the easy availability more effective and medically proven drugs. Furthermore, with the mass production and accessibility of these antiviral drugs they became cost effective and also gained popularity in the healthcare sector. Thus, the global anti-viral therapies market has experienced an enormous growth in recent years.

Benefits of Anti-Viral Therapies

As per a Research Dive blog , antiviral therapies work best when started soon after flu illness arise. When treatment is started within 48 hours of becoming sick with virus symptoms, antiviral drugs reduces the flu symptoms and fever, and also cuts the time for the sick patient by about one day. Antiviral drugs also reduce the risk of complications such as respiratory complications requiring antibiotics, ear infections in children, and hospitalization in adults. For people at high risk of serious flu complications, an early treatment provided with an antiviral drug may prove in having milder illness instead of more severe illness where the patient needs to be hospitalized. According to some studies, antiviral drugs can also reduce the risk of death in adults with flu illness.

Targeted Efforts towards Better Global Healthcare

There are a number of reasons behind getting a viral infection and also there are times when these infections may expose as a side effect of other medical treatments. Viral infections are the side effects of the treatment for HIV, respiratory disorders, cancer, diabetes, and other such diseases. There has been a rising demand for antiviral therapies owing to the growing prevalence of these major diseases. Indeed, this has helped in up-surging the growth of global anti-viral therapies market to newer heights. Additionally, with technological, sociological, and economical advancements, considerable efforts have been made towards achieving a robust and strong healthcare infrastructure across the globe. The outspread and range of antiviral drugs has grown progressively with the help of targeted efforts from organizations such as WHO and Red Cross, which has undoubtedly aided in the growth of the global anti-viral therapies market.

Future of Anti-Viral Therapies Market

Global market for anti-viral therapies is predicted to witness a robust growth during the forecast period from 2019 to 2026. Several factors such as rising public awareness regarding viral infections, growth in healthcare spending, increasing investments on R&D, and occurrence of life-threatening diseases are expected to surge the demand for anti-viral therapies market growth.

Expenses involved in the production of antiviral drugs, and growth in the demand for alternative medicines such as naturopathy and homeopathy are projected to hinder the market growth. In addition, increasing preventive measures and awareness about the availability of vaccines for viral infections will also act as a restraint to the market growth for anti-viral therapies.

Rising occurrence of viral infection all across the globe will give significant uplift to the growth of the global market in the coming years. As per the Research Dive report statistics, the global anti-viral therapies market is anticipated to grow at 5.8% CAGR and will surpass $75.6 billion during the period of forecast. The report highlights key players operating in the global market. Some of them are Abbott Laboratories, Gilead Sciences, AbbVie Inc., GlaxoSmithKline, F. Johnson & Johnson, Hoffmann-La Roche Ltd., Brislutol-Myers-Squibb, Schering-Plough Corporation, and Merck & Co., Inc., and AstraZeneca Plc. These players are adopting several strategies such as collaborations, product development, and are also initiating R&D activities to stand strong in the global market.

Purchase Options

Inquire To Buy

Personalize this research

  • Triangulate with your own data
  • Request your format and definition
  • Get a deeper dive on a specific application, geography, customer or competitor
10% Off on Customization
Contact Us

Customers Also Viewed